Malignant Pleural Effusion Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
DelveInsight’s, “Malignant Pleural Effusion Pipeline Insight 2025” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Malignant Pleural Effusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Malignant Pleural Effusion Pipeline Report to explore emerging therapies, key Malignant Pleural Effusion Companies, and future Malignant Pleural Effusion treatment landscapes @ Malignant Pleural Effusion Pipeline Outlook Report
Key Takeaways from the Malignant Pleural Effusion Pipeline Report
- DelveInsight’s Malignant Pleural Effusion pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Malignant Pleural Effusion treatment.
- The leading Malignant Pleural Effusion Companies such as LIPAC Oncology, RS Oncology, Clover Biopharmaceuticals, Gongwin Biopharm Holdings, Simcere Pharmaceutical Group and others.
- Promising Malignant Pleural Effusion Pipeline Therapies such as Abnoba Viscum F 20mg, Bevacizumab, Cisplatin, RSO-021, Endostar, zoledronic acid, Vinorelbine, Docetaxel, Gemcitabine and others.
Stay ahead with the most recent pipeline outlook for Malignant Pleural Effusion. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Malignant Pleural Effusion Treatment Drugs
Malignant Pleural Effusion Emerging Drugs Profile
- LEITP-1009: LIPAC Oncology
LIPAC is developing a new Liposomal Enhanced IntraThoracic Paclitaxel (LEITP) for the treatment of MPM utilizing the LiPax technology. Currently, the drug is being developed in the Pre-Clinical stage of clinical trial evaluation for the treatment of Malignant Pleural Effusion.
- RSO-021: RS Oncology
RSO-021 is a novel irreversible inhibitor of a key mitochondrial enzyme PRX3 (upregulated in cancer cells) regulating oxidative stress pathways. Treatment with RSO-021 will be administered weekly via an intrapleural catheter after routine pleural effusion drainage. RSO-021 therapy has proven to significantly reduce pre-clinically tumor burden in malignant mesothelioma and other cancer types by inhibiting three key enzymes in the antioxidant signaling network within the mitochondria. Covalent adduction of the active site of a key mitochondrial enzyme by RSO-021 inactivates the peroxidase activity of the enzymes leading to accumulation of hydrogen peroxide to levels incompatible with tumor cell survival, while preserving healthy normal cells. RSO-021 is being developed for the treatment of malignant pleural effusion (MPE) via intrapleural (IP) installation in patients suffering from mesothelioma, breast cancer and other indications causing MPE.
- SCB-313: Clover Biopharmaceuticals
SCB-313, has been designed and developed utilizing the Trimer-Tag™ technology platform. SCB-313 is a covalently-linked, native-like trimeric fusion protein which is structurally and functionally differentiated from the dimeric antibody-based structures and other native ligand-based candidates targeting this pathway. SCB-313 has the potential to address the unmet global need for the treatment of intracavitary malignancies, including Malignant Ascites (MA), Malignant Pleural effusions (MPE), and Peritoneal carcinomatosis (PC), as well as additional cancer indications.
The Malignant Pleural Effusion Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Malignant Pleural Effusion with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Effusion treatment.
- Malignant Pleural Effusion Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Malignant Pleural Effusion Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Malignant Pleural Effusion market.
Explore groundbreaking therapies and clinical trials in the Malignant Pleural Effusion Pipeline. Access DelveInsight’s detailed report now! @ New Malignant Pleural Effusion Drugs
Malignant Pleural Effusion Companies
LIPAC Oncology, RS Oncology, Clover Biopharmaceuticals, Gongwin Biopharm Holdings, Simcere Pharmaceutical Group and others.
Malignant Pleural Effusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Malignant Pleural Effusion Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Unveil the future of Malignant Pleural Effusion Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Malignant Pleural Effusion Market Drivers and Barriers
Scope of the Malignant Pleural Effusion Pipeline Report
- Coverage- Global
- Malignant Pleural Effusion Companies- LIPAC Oncology, RS Oncology, Clover Biopharmaceuticals, Gongwin Biopharm Holdings, Simcere Pharmaceutical Group and others.
- Malignant Pleural Effusion Pipeline Therapies- Abnoba Viscum F 20mg, Bevacizumab, Cisplatin, RSO-021, Endostar, zoledronic acid, Vinorelbine, Docetaxel, Gemcitabine and others.
- Malignant Pleural Effusion Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Malignant Pleural Effusion Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Malignant Pleural Effusion Drug development? Find out in DelveInsight’s exclusive Malignant Pleural Effusion Pipeline Report—access it now! @ Malignant Pleural Effusion Emerging Drugs and Major Companies
Table of Content
- Introduction
- Executive Summary
- Malignant Pleural Effusion: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Malignant Pleural Effusion – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/ II)
- RSO-021: RS Oncology
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- LEITP-1009: LIPAC Oncology
- Drug profiles in the detailed report…..
- Inactive Products
- Malignant Pleural Effusion Key Companies
- Malignant Pleural Effusion Key Products
- Malignant Pleural Effusion – Unmet Needs
- Malignant Pleural Effusion – Market Drivers and Barriers
- Malignant Pleural Effusion – Future Perspectives and Conclusion
- Malignant Pleural Effusion Analyst Views
- Malignant Pleural Effusion Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/malignant-pleural-effusion-pipeline-insight
